Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98,567,360
-
Number of holders
-
182
-
Total 13F shares, excl. options
-
76,226,291
-
Shares change
-
+4,927,610
-
Total reported value, excl. options
-
$958,937,526
-
Value change
-
+$63,838,690
-
Put/Call ratio
-
2.15%
-
Number of buys
-
96
-
Number of sells
-
-74
-
Price
-
$12.58
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q1 2025
215 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 182 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 76,226,291 shares
of 98,567,360 outstanding shares and own 77.33% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (10,860,977 shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (10,514,657 shares), ORBIMED ADVISORS LLC (8,288,510 shares), BlackRock, Inc. (4,298,988 shares), SR One Capital Management, LP (4,012,903 shares), ALLIANCEBERNSTEIN L.P. (3,922,805 shares), VANGUARD GROUP INC (3,488,293 shares), STATE STREET CORP (2,031,234 shares), FRANKLIN RESOURCES INC (1,857,544 shares), and Cormorant Asset Management, LP (1,600,000 shares).
This table shows the top 182 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.